# 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

> **NCT06592326** · PHASE3 · RECRUITING · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 460 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** 9MW2821
- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin/Carboplatin

## Key facts

- **NCT ID:** NCT06592326
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2027-09
- **Final completion:** 2028-12
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592326, "9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06592326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*